HK-listed CStone Pharma jumps most in nearly 16 weeks on new drug approval

CStone Pharmaceuticals

21/12/2021 07:51

** Shares of CStone Pharmaceuticals  2616.HK  rise 5.1% to
HK$8.47, on track for their biggest daily percentage gain since
Sept. 2
    ** Co says China's National Medical Products Administration
has approved new drug application for its anti-PDL1 monoclonal
antibody Cejemly® in combination with chemotherapy for lung
cancer cell treatment  urn:newsml:reuters.com:*:nFWN2T50VO
    ** Shanghai-based biopharmaceutical products developer says
it formed a strategic collaboration agreement with Pfizer
 PFE.N  
    ** Agreement includes development and commercialisation of
Cejemly® in mainland China and a framework to bring additional
oncology assets to the Greater China market
    ** The Hang Seng Commerce & Industry Index  .HSNC  and the
healthcare index  .HSCIH  both surge 2.4%
    ** The Hang Seng Composite Index  .HSCI  rises 1.7% and the
benchmark Hang Seng Index  .HSI  climbs 1.5%
    ** Stock up after two straight sessions of falls; had fallen
20% this year, as of last close

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))